Keywords
How to Cite
Abstract
Nasal T/NK non-Hodgkin´s lymphoma is a rare and aggressive variant of non-Hodgkin´s lymphoma. CHOP based chemotherapy is the most frequent treatment. However, during the last years there have been reports of different chemotherapy regimens, followed by high dose chemotherapy with stem cell support, with promising results. We report the case of a male patient with nasal T/NK non-Hodgkin´s lymphoma, treated with DDGP regimen, followed by autologous bone marrow transplant.
References
Yamaguchi N, Kwong YL, Kim WS et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural Killer (NK)/ T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410-4416.
Li X, Cui Y, Sun Z et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-Cell lymphoma: A randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016;22(21):5223-5228.
Terro K, Sharrouf L, El Cheikh J. Progress of hematopoietic
stem cell transplantation and radiotherapy in the treatment of extranodal NK/T cell lymphoma. Front Oncol. 2022 Feb 16;12:832428.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar